NasdaqGS:BCRXBiotechs
BioCryst Pharmaceuticals (BCRX) Is Up 9.0% After Navenibart ALPHA-SOLAR Data And Astria Deal News – Has The Bull Case Changed?
BioCryst Pharmaceuticals recently acquired Astria Therapeutics for about US$700.00 million and announced that it has presented nine hereditary angioedema abstracts, including new data on ORLADEYO and long-acting antibody navenibart, at the 2026 AAAAI Annual Meeting.
Beyond expanding its hereditary angioedema portfolio, the company’s positive interim ALPHA-SOLAR trial results for navenibart highlight a potential shift toward less frequent, long-acting preventive treatment options.
We’ll now...